Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Benjamin Cravatt
AddedFeb 13, 2024
UpdatedMay 31, 2026
Benjamin Cravatt

Benjamin Cravatt

Co-Founder, Boundless Bio

CrunchbaseThe Org

Benjamin Cravatt's Career

Boundless Bio
Boundless Bio

Los Angeles, CA, US

Co-Founder
Kojin Therapeutics
Kojin Therapeutics

Cambridge, MA, US

Co-Founder
Vividion Therapeutics
Vividion Therapeutics

San Diego, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Benjamin Cravatt's Career

Boundless Bio
Boundless Bio
Series C$251.4M1752018Los Angeles, CA, US
Co-Founder

Leadership at Boundless Bio

Jennifer LewJennifer LewBoard Member
Zachary HornbyZachary HornbyCEO
Jakob LovenJakob LovenBoard Member
Jonathan Lim, M.D.Jonathan Lim, M.D.Co-Founder

Similar to Boundless Bio

Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Modifi BioModifi BioNew Haven, CT, USCancer Therapeuticsest. 2021Modifi BioNew Haven, CT, US · est. 2021

Modifi Biosciences: Pioneering DNA modification for innovative cancer therapeutics.

Seed · $13.1M34
Kojin Therapeutics
Kojin Therapeutics
Series A$60M252020Cambridge, MA, US
Co-Founder

Leadership at Kojin Therapeutics

Thomas CahillThomas CahillBoard Member
Vasanthi ViswanathanVasanthi ViswanathanCo-Founder
Gini DeshpandeGini DeshpandeBoard Member
Amir NashatAmir NashatBoard Member
Luba GreenwoodLuba GreenwoodBoard Member
Stuart SchreiberStuart SchreiberCo-Founder

Similar to Kojin Therapeutics

Kymera TherapeuticsKymera TherapeuticsWatertown, MA, USDrugsest. 2017Kymera TherapeuticsWatertown, MA, US · est. 2017

Kymera Therapeutics, a global biopharmaceutical firm, innovates drugs for untreatable acute and chronic diseases.

Public · $879M167
Z SquaredZ SquaredWexford, PA, USPharmaceuticalsest. 1996Z SquaredWexford, PA, US · est. 1996

Coeptis Therapeutics: Developing and acquiring pharmaceutical products through strategic partnerships.

Public · $11M10
Kinaset TherapeuticsKinaset TherapeuticsMedfield, MA, USRespiratory Drugsest. 2020Kinaset TherapeuticsMedfield, MA, US · est. 2020

Kinaset Therapeutics develops novel respiratory drugs to address unmet medical needs.

Series A · $41.5M11
Vividion Therapeutics
Vividion Therapeutics
Acquired$371.5M02013San Diego, CA, US
Co-Founder

Leadership at Vividion Therapeutics

John ClarkeJohn ClarkeBoard Member
Phil BaranPhil BaranCo-Founder
Paul SchimmelPaul SchimmelBoard Member
Tom WoiwodeTom WoiwodeBoard Member
Jin-Quan YuJin-Quan YuCo-Founder
Aleksandra RizoAleksandra RizoBoard Member

Benjamin Cravatt's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Benjamin Cravatt

Gregory L. VerdineGregory L. VerdineCo-Founder · Wave Life SciencesCraig CrewsCraig CrewsFounder · ArvinasThomas CechThomas CechBoard Member · Merck & CO INC Cedear EAC 5 REAlexander KlibanovAlexander KlibanovFounder · PulmatrixStephen BenkovicStephen BenkovicCo-Founder · BoragenSamir MitragotriSamir MitragotriFounder · i2o Therapeutics